Insmed (NASDAQ: INSM) — Company Overview, News & Financial Data
Insmed is a biopharmaceutical company focused on developing treatments for serious and rare diseases, including NTM lung disease.
Insmed
Insmed is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. Headquartered in Bridgewater, New Jersey, the company specializes in treatments for complex pulmonary disorders. Its commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is approved for refractory Mycobacterium avium complex (MAC) lung disease. Insmed's development pipeline includes brensocatib, a dipeptidyl peptidase 1 (DPP1) inhibitor being evaluated for non-cystic fibrosis bronchiectasis, and treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company maintains research and commercial operations across North America, Europe, and Japan.
Snapshot
Operations
Products and/or services of Insmed
- ARIKAYCE (Amikacin Liposome Inhalation Suspension): A commercial inhaled antibacterial therapy approved for treating Mycobacterium avium complex lung disease as part of a combination regimen for adult patients who have limited or no alternative treatment options.
- Brensocatib Development: An investigational oral dipeptidyl peptidase 1 inhibitor designed to treat non-cystic fibrosis bronchiectasis and other neutrophil-mediated inflammatory diseases, currently advancing through late-stage global Phase 3 clinical evaluations.
- Treprostinil Palmitil Inhalation Powder: A dry powder formulation of a long-acting synthetic prostacyclin analog in clinical development for treating patients suffering from pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
- Gene Therapy Research: An early-stage research initiative utilizing viral vector delivery technologies and novel capsid engineering to develop gene therapies for severe rare genetic disorders affecting pulmonary, central nervous, and muscular systems.
- Preclinical Respiratory Therapeutics: Research operations conducting preclinical studies on small molecules and biologics aimed at treating rare respiratory diseases, severe fibrotic conditions, and refractory pulmonary infections across global research centers.
- Global Commercialization Network: Targeted pharmaceutical distribution, medical affairs support, and specialty distribution networks delivering therapies to patients across key commercial markets including the United States, European Union member states, and Japan.
Insmed executive team
- William H. LewisPresident, CEO & Chairman
- Sara M. BonsteinChief Financial Officer
- Roger AdsettChief Operating Officer
- Michael Alexander SmithChief Legal Officer & Corporate Secretary
- Martina FlammerChief Medical Officer
- Brian K. KasparChief Scientific Officer
- Bryan DunnVice President of Investor Relations
- Christie CamelioChief Compliance Officer
- Claire MulhearnVice President of Corporate Communications
- S. Nicole SchaefferChief People Strategy Officer